查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1522994

双极性情感障碍治疗药物市场报告：2030 年趋势、预测与竞争分析

Bipolar Disorder and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

双相情感障碍治疗药物的趋势和预测

预计 2024 年至 2030 年，全球双相情感障碍治疗药物市场将以 3.7% 的复合年增长率成长。该市场的主要驱动因素是人们对心理健康的认识不断提高以及双相情感障碍盛行率的上升。全球双极性情感障碍药物市场的未来看起来充满希望，口服和肠胃外药物市场充满机会。

按细分市场分類的双相情感障碍治疗药物趋势

本研究按药物类别、给药途径、作用机制和区域提供双极性情感疾患药物的全球市场预测。

双极性情感障碍药物市场洞察

Lucintel 预测，由于精神病症状病例的增加，抗精神病药物在预测期内仍将是最大的细分市场。

由于口服药物的给药灵活性和成本效益，其仍将是该市场的最大细分市场。

由于双极性情感障碍盛行率不断上升，北美在预测期内仍将是最大的地区。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球双极性情感疾患治疗药物市场预计将以3.7%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 这个市场的主要驱动力是心理健康意识的提高和躁郁症盛行率的上升。

Q3.市场的主要细分市场是：

A3. 双极性情感障碍药物市场前景广阔，口服和注射药物市场都有机会。

Q4.市场的主要企业是：

A4. 生产双极性情感疾患治疗药物的主要企业如下：

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计，由于精神病症状病例数量不断增加，抗精神病药物在预测期内仍将是其最大的细分市场。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 由于双极性情感疾患的盛行率不断上升，北美在预测期内仍将是最大的地区。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球双极性情感疾患治疗药物市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 双相情感障碍治疗药物的全球市场趋势（2018-2023）和预测（2024-2030）
  • 按药物类别分類的全球双极性情感障碍治疗药物市场
    • 情绪稳定剂
    • 抗惊厥药
    • 抗精神病药
    • 抗忧郁症
    • 抗焦虑药
  • 途径分類的全球双极性情感障碍治疗药物市场
    • 口腔医学
    • 肠外药物
    • 其他的
  • 按作用机转分類的双极性情感疾患治疗药物的全球市场
    • 选择性血清素再回收抑制剂
    • 正肾上腺素再回收抑制剂
    • 三环抗忧郁药物
    • β阻断剂
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球双极性情感障碍治疗药物市场（按地区）
  • 北美双相情感障碍药物市场
  • 欧洲双极性情感障碍药物市场
  • 亚太双向情感障碍药物市场
  • 其他区域双极性情感障碍治疗药物市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球双极性情感疾患治疗药物市场成长机会（依药物类别）
    • 按给药途径的全球双相情感障碍治疗药物市场成长机会
    • 全球双极性情感障碍治疗药物市场成长机会（按作用机制）
    • 全球双极性情感障碍治疗药物市场成长机会（按地区）
  • 全球双相情感障碍药物市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大双极性情感障碍药物市场的全球容量
    • 全球双极性情感障碍药物市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis
简介目录

Bipolar Disorder and Treatment Trends and Forecast

The future of the global bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets. The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030. The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Bipolar Disorder and Treatment by Segment

The study includes a forecast for the global bipolar disorder and treatment by drug class, route of administration, mechanism of action, and region.

Bipolar Disorder and Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Mood Stabilizer
  • Anticonvulsants
  • Anti-Psychotic Drugs
  • Anti-Depressant Drugs
  • Anti-Anxiety Drugs

Bipolar Disorder and Treatment Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral
  • Others

Bipolar Disorder and Treatment Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

  • Selective Serotonin Reuptake Inhibitor
  • Serotonin Norepinephrine Reuptake Inhibitor
  • Tricyclic Antidepressant Drug
  • Beta Blockers
  • Others

Bipolar Disorder and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Bipolar Disorder and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bipolar disorder and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bipolar disorder and treatment companies profiled in this report include-

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis

Bipolar Disorder and Treatment Market Insights

Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Within this market, oral will remain the largest segment due to its enhanced dosing flexibility and cost-effectiveness.

North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Features of the Global Bipolar Disorder and Treatment Market

Market Size Estimates: Bipolar disorder and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bipolar disorder and treatment market size by drug class, route of administration, mechanism of action, and region in terms of value ($B).

Regional Analysis: Bipolar disorder and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, route of administration, mechanism of action, and regions for the bipolar disorder and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bipolar disorder and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for bipolar disorder and treatment market?

Answer: The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the bipolar disorder and treatment market?

Answer: The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

Q3. What are the major segments for bipolar disorder and treatment market?

Answer: The future of the bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets.

Q4. Who are the key bipolar disorder and treatment market companies?

Answer: Some of the key bipolar disorder and treatment companies are as follows:

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis

Q5. Which bipolar disorder and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Q6. In bipolar disorder and treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the bipolar disorder and treatment market by drug class (mood stabilizer, anticonvulsants, anti-psychotic drugs, anti-depressant drugs, and anti-anxiety drugs), route of administration (oral, parenteral, and others), mechanism of action (selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, tricyclic antidepressant drug, beta blockers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Bipolar Disorder and Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Bipolar Disorder and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Bipolar Disorder and Treatment Market by Drug Class
    • 3.3.1: Mood Stabilizer
    • 3.3.2: Anticonvulsants
    • 3.3.3: Anti-Psychotic Drugs
    • 3.3.4: Anti-Depressant Drugs
    • 3.3.5: Anti-Anxiety Drugs
  • 3.4: Global Bipolar Disorder and Treatment Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
    • 3.4.3: Others
  • 3.5: Global Bipolar Disorder and Treatment Market by Mechanism of Action
    • 3.5.1: Selective Serotonin Reuptake Inhibitor
    • 3.5.2: Serotonin Norepinephrine Reuptake Inhibitor
    • 3.5.3: Tricyclic Antidepressant Drug
    • 3.5.4: Beta Blockers
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Bipolar Disorder and Treatment Market by Region
  • 4.2: North American Bipolar Disorder and Treatment Market
    • 4.2.1: North American Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.2.2: North American Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
  • 4.3: European Bipolar Disorder and Treatment Market
    • 4.3.1: European Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.3.2: European Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
  • 4.4: APAC Bipolar Disorder and Treatment Market
    • 4.4.1: APAC Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.4.2: APAC Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
  • 4.5: ROW Bipolar Disorder and Treatment Market
    • 4.5.1: ROW Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.5.2: ROW Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Mechanism of Action
    • 6.1.4: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Region
  • 6.2: Emerging Trends in the Global Bipolar Disorder and Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Bipolar Disorder and Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bipolar Disorder and Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GlaxoSmithKline
  • 7.2: Pfizer
  • 7.3: Eli Lily
  • 7.4: AbbVie
  • 7.5: Otsuka Holdings
  • 7.6: AstraZeneca
  • 7.7: Novartis